Clinical trial
The Randomized, Controlled Clinical Trial of Apatinib Plus CIK as the Third Line Therapy for Lung Adenocarcinoma Patients With Wild-Type EGFR
NCT02493582 is registered in ClinicalTrials.gov with The First People's Hospital of Changzhou as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Randomized, Controlled Clinical Trial of Apatinib Plus CIK as the Third Line Therapy for Lung Adenocarcinoma Patients With Wild-Type EGFR
- Lead sponsor
- The First People's Hospital of Changzhou
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- July 31, 2015
- Completion date
- July 31, 2033
- Enrollment
- 400 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.